Screening of prognostic factors and comparing of staging systems of multiple myeloma.
- Author:
Jia LI
1
;
Xue-Bin WU
;
Yue ZHOU
;
Xuan WANG
;
Jian-Xin CHEN
Author Information
1. Department of Hematology, Capital Medical University, Beijing, China. lj7295@yahoo.com.cn
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Female;
Humans;
Male;
Middle Aged;
Multiple Myeloma;
diagnosis;
pathology;
Multivariate Analysis;
Neoplasm Staging;
Prognosis
- From:
Journal of Experimental Hematology
2012;20(4):926-929
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the clinical features and laboratory data of 56 patients with multiple myeloma (MM), find the potential prognostic factors and compare Durie Salmon staging system with International Staging System for patients classification. The median survival time was calculated by the Kaplan Meier, and survival curves were compared using the Log-Rank test. Potential prognostic factors were evaluated by univariate and multivariate analyses. Bivariate correlation of Durie Salmon staging system with International Staging System were analyzed. The results showed that the median survival time of the patients was 42.7 months. Prognostic factors identified as adversely affecting survival included low levels of hemoglobin, platelet, serum albumin, high levels of lactate dehydrogenase, creatinine, C-reactive, serum β2-microglobulin and high proportion of plasma cells in bone marrow. Among them, only hemoglobin level had independent prognostic value in MM. Durie Salmon staging system significantly correlated with International Staging System. In DS staging system, significant survival differences were found between patients in stages I and III, but statistically significant survival differences were observed among the all three stages in International Staging System. It is concluded that hemoglobin, platelet, serum albumin, lactate dehydrogenase, creatinine, C-reactive, β2-microglobulin and the number of plasma cells in bone marrow have clinical value for evaluating the prognosis of MM patients. International Staging System can significantly distinguish three clinical stages of MM patients.
